title: Development of an HPLC method for monitoring of Photofrin II therapy.
abstract: OBJECTIVE
  To develop and to validate a method to quantify plasma porphyrins after application of Photofrin II, a drug preparation that is used for photodynamic therapy (PDT) and as a radiosensitizer.
  
  
  METHODS
  After solid phase extraction of postdose plasma samples, reversed phase high performance-liquid chromatography with fluorescence detection was performed. Plasma porphyrin concentrations were monitored in five patients that were treated with Photofrin II.
  
  
  RESULTS
  The method proved linear over a wide concentration range, precise, and applicable in a routine clinical laboratory setting.
  
  
  CONCLUSIONS
  The method described here will enable large-scale clinical pharmacokinetic studies on Photofrin II; investigations can now address possible correlations between individual concentrations of drug-derived plasma porphyrins and systemic photosensitivity--representing the main side effect of Photofrin II--with the perspective of individualized light protection regimens after Photofrin II administration.
authors.affiliation: Institute of Clinical Chemistry, Hospital of the University of Munich, Munich, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Vogeser
authors.forename: Moshe
authors.initials: M
authors.lastname: Schaffer
authors.forename: Emil
authors.initials: E
authors.lastname: Egeler
authors.forename: Ute
authors.initials: U
authors.lastname: Spöhrer
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002623:Chemistry Techniques, Analytical / Q000379:methods*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D017323:Dihematoporphyrin Ether / Q000494:pharmacology*; D006801:Humans; D010778:Photochemotherapy; D010949:Plasma / Q000187:drug effects / Q000378:metabolism; D011166:Porphyrins / Q000737:chemistry / Q000378:metabolism; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D011166:Porphyrins; D017323:Dihematoporphyrin Ether